{
    "news_source": "nasdaq",
    "news_id": "nasdaq_4936d01c58b7",
    "news_header": "OncoCyte Corp. announced a $29.1 million funding round led by major shareholders, including Bio-Rad, to support its diagnostic technology.",
    "news_original_title": "Oncocyte Secures $29.1Mln Funding Led By Bio-Rad To Advance Transplant Diagnostics, Stock Down",
    "news_text": "OncoCyte Corp. (OCX), a diagnostics technology company, has announced securities purchase agreements for a registered direct offering and a private placement, expected to generate $29.1 million at $2.05 per share. The funding round is led by OncoCyte&#x27;s five largest shareholders, including Bio-Rad Laboratories. The offering includes both registered direct and private placement shares, with transactions expected to close around February 10. Bio-Rad will also provide additional financial support for a clinical trial and commercialization efforts, enhancing their partnership with OncoCyte. The funds will help fully develop OncoCyte&#x27;s FDA In-Vitro Diagnostic transplant assay program, crucial for revenue growth. Currently, OCX is trading at $2.01 on Nasdaq.",
    "news_url": "https://www.nasdaq.com/articles/oncocyte-secures-291mln-funding-led-bio-rad-advance-transplant-diagnostics-stock-down",
    "news_time": 1739192640.0,
    "news_categories": [
        "business",
        "markets"
    ],
    "news_source_lang": "en",
    "news_group": -1
}